Alx Oncology Holdings (ALXO) - Total Liabilities
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has total liabilities worth $26.98 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alx Oncology Holdings - Total Liabilities Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's total liabilities have evolved over time, based on quarterly financial data. See ALXO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Alx Oncology Holdings Competitors by Total Liabilities
The table below lists competitors of Alx Oncology Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TRG Latin America Acquisitions Corp. Class A Ordinary Shares
NASDAQ:TRGS
|
USA | $12.52 Million |
|
JINSUNG T.E.C. Inc
KQ:036890
|
Korea | ₩216.64 Billion |
|
China Rare Earth Holdings Limited
F:RAE
|
Germany | €107.22 Million |
|
Smart Sand Inc
NASDAQ:SND
|
USA | $100.32 Million |
|
Bank Amar Indonesia
JK:AMAR
|
Indonesia | Rp2.21 Trillion |
|
HomeChoice Investments Ltd
JSE:HIL
|
South Africa | ZAC4.43 Billion |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
China | $32.26 Billion |
|
Taisol Electronics Co Ltd
TW:3338
|
Taiwan | NT$1.66 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Alx Oncology Holdings 's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALXO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alx Oncology Holdings 's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alx Oncology Holdings (2018–2025)
The table below shows the annual total liabilities of Alx Oncology Holdings from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.06 Million | -3.20% |
| 2024-12-31 | $34.16 Million | -35.36% |
| 2023-12-31 | $52.84 Million | +22.81% |
| 2022-12-31 | $43.02 Million | +151.11% |
| 2021-12-31 | $17.13 Million | +175.95% |
| 2020-12-31 | $6.21 Million | -43.31% |
| 2019-12-31 | $10.95 Million | +445.15% |
| 2018-12-31 | $2.01 Million | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more